Placental growth factor in suspected preterm pre-eclampsia: a review of the evidence and practicalities of implementation.

A Hurrell, A Beardmore-Gray, K Duhig, L Webster, L C Chappell, A H Shennan

BJOG : an international journal of obstetrics and gynaecology 2020 Dec

filter terms:

Despite extensive research, the pathophysiology and prevention of pre-eclampsia remain elusive, diagnosis is challenging, and pre-eclampsia remains associated with adverse maternal and perinatal outcomes. Angiogenic biomarkers, including placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFlt-1), have been identified as valuable biomarkers for preterm pre-eclampsia, accelerating diagnosis and reducing maternal adverse outcomes by risk stratification, with enhanced surveillance for high-risk women. PlGF-based testing is increasingly being implemented in clinical practice in several countries. This review provides healthcare providers with an understanding of the evidence for PlGF-based testing and describes the practicalities and challenges to implementation. TWEETABLE ABSTRACT: Placental growth factor in pre-eclampsia: evidence and implementation of testing. © 2020 Royal College of Obstetricians and Gynaecologists.

Citation

A Hurrell, A Beardmore-Gray, K Duhig, L Webster, L C Chappell, A H Shennan. Placental growth factor in suspected preterm pre-eclampsia: a review of the evidence and practicalities of implementation. BJOG : an international journal of obstetrics and gynaecology. 2020 Dec;127(13):1590-1597